You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes

Article type: Correction

Authors: Driscoll, Iraa; b; c | Ma, Yueb | Gallagher, Catherine L.d; e | Johnson, Sterling C.a; b; d | Asthana, Sanjaya; b; d | Hermann, Bruce P.a; b; e | Sager, Mark A.a; b | Blennow, Kajf; g | Zetterberg, Henrikf; g; h; i | Carlsson, Cynthia M.a; b; d | Engelman, Corinne D.a; b; j | Dubal, Dena B.k | Okonkwo, Ozioma C.a; b; d

Affiliations: [a] Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA | [b] Wisconsin Alzheimer’s Institute, Madison, WI, USA | [c] Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI, USA | [d] Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, WI, USA | [e] Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA | [f] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden | [g] Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden | [h] Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK | [i] UK Dementia Research Institute at UCL, London, UK | [j] Departments of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA | [k] Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA

DOI: 10.3233/JAD-219006

Journal: Journal of Alzheimer's Disease, vol. 82, no. 3, pp. 1369-1370, 2021

Published: 03 August 2021
Get PDF

[Journal of Alzheimer’s Disease, 79 (3) (2021), 1297–1305 DOI 10.3233/JAD-200944]

https://content.iospress.com/articles/journal-of-alzheimers-disease/jad200944

On p. 1299, in the Results section, where it says:

We have also assessed how many of the participants in this sample would be considered abnormal or negative based on our center’s derived cutpoint for CSF AD biomarkers [32], namely Aβ42 (≤471.54), pTau (≥59.5), and tTau (≥461.26). Majority of the participants in our sample were negative for both Aβ and tau biomarkers. Based on χ2-tests, the percentage of those who were Aβ42 negative did not significantly differ between KL-VS heterozygotes (7%) versus non-carriers (12%) (p = 0.18). Similarly, the percentage of those who were negative based on pTau did not significantly differ between KL-VS heterozygotes (18%) and non-carriers (13%) (p = 0.27). Finally, based on the tTau measure, the percentage of those who were negative did not significantly differ between KL-VS heterozygotes (16%) and noncarriers (14%) (p = 0.42).

It should be:

We have also assessed how many of the participants in this sample would be considered positive (i.e., abnormal) based on our center’s derived cutpoint for CSF AD biomarkers [32], namely Aβ42 (≤471.54), pTau (≥59.5), and tTau (≥461.26). Majority of the participants in our sample were negative for both Aβ42 and tau biomarkers. Based on χ2-tests, the percentage of those who were Aβ42 positive did not significantly differ between KL-VS heterozygotes (7%) versus non-carriers (12%) (p = 0.18). Similarly, the percentage of those who were positive based on pTau did not significantly differ between KL-VS heterozygotes (18%) and non-carriers (13%) (p = 0.27). Finally, based on the tTau measure, the percentage of those who were positive did not significantly differ between KL-VS heterozygotes (16%) and non-carriers (14%) (p = 0.42).

Show more